The Pharma Data

JANUARY 31, 2021

Clover plans to initiate a global Phase 2/3 efficacy trial of its protein-based S-Trimer COVID-19 vaccine candidate adjuvanted with Dynavax’s CpG 1018 plus alum in the first half of 2021 with an interim analysis for vaccine efficacy potentially in the middle of 2021. About Trimer-Tag© Technology.

Vaccination 52

Vaccination Vaccine Trials Protein 52

The Pharma Data

NOVEMBER 29, 2021

1.1.529 a variant of concern, named Omicron, on the advice of WHO’s Technical Advisory Group on Virus Evolution (TAG-VE). Effectiveness of prior SARS-CoV-2 infection. WHO will continue to provide updates as more information becomes available, including following meetings of the TAG-VE. Source link: [link].

Vaccination 52

Vaccination Vaccine Genome Genomics 52

The Pharma Data

MARCH 8, 2022

The development of visage SARS-CoV-2 or pansarbecovirus vaccines, as well as the development of vaccines that are suitable to evoke mucosal impunity, may be desirable options, but the timeframe for their development and product is uncertain. 2 has been adding relative to BA.1 2 following infection with BA.1

Vaccination 52

Vaccination Vaccine Manufacturing Development 52

The Pharma Data

APRIL 22, 2023

Cocktail of modified antibodies provides strong effect against SARS-CoV-2 Is it possible to improve the antibodies that the body produces to fight SARS-CoV2? The researchers have access to many antibodies against SARS-CoV-2, of which eight are of the IgG3 type. Source link: [link]

Antibody 40

Antibody Immune Response Protein Research 40

XTalks

NOVEMBER 27, 2021

The World Health Organization (WHO) has declared the new variant of SARS-CoV-2 found in South Africa, first referred to as B.1.1.529, The technical advisory group on SARS-CoV-2 virus evolution (TAG-VE) met on Friday to discuss B.1.1.529,

Vaccination 97

Vaccination Vaccine Protein Scientist 97

The Pharma Data

NOVEMBER 15, 2020

Clover aims to double its commercial manufacturing capacity in preparation for global Phase 2/3 trials. With promising preliminary safety and immunogenicity results from the Phase 1 clinical study, Clover aims to quickly expand its current 2 x 2000L capacity of the Cytiva FlexFactory, which went into service in January 2020.

Vaccination 52

Vaccination Vaccine Manufacturing Life Science 52

The Pharma Data

MARCH 20, 2021

As laboratories around the world tackle the challenges of screening large numbers of samples for SARS-CoV-2, the managers of these labs have turned to the use of automation to address some key concerns. SARS-CoV-2 qPCR workflow that had been implemented over the summer at their facility. presented the.

Reagent 52

Reagent RNA Bioinformatics Medicine 52

Delveinsight

DECEMBER 3, 2020

The FDA nods for the Elecsys Anti-SARS-CoV-2 S quantitative antibody test that runs on Roche’s cobas e analyzers, follows its September launch in Europe after receiving a CE mark. Ovid showed a phase 2 data on OV101 in Angelman, a genetic nervous system disorder, in 2018.

Gene Therapy 52

Gene Therapy Gene Antibody Research 52

Rethinking Clinical Trials

AUGUST 4, 2022

It is a single injection of peginterferon lambda verses placebo, patients were randomized within 7 days of symptom onset and positive SARS-CoV-2 test. The arm evaluating Peginterferon Lambda is a multicenter, investigator sponsored, randomized placebo-controlled Phase 3 study in Brazil with 12 sites and Canada (5 sites).

Trials 130

Trials Vaccination Vaccine Clinical Trials 130

Drug Discovery World

NOVEMBER 13, 2023

De Luca will present on Tripkin, a best-in-class potential for tumour-targeted interleukin-2 (IL2) potentiated by tumour necrosis facor (TNF). Fabian Mohr, PhD, Vice President Research & Development, IBA Lifesciences, on: ‘Developing a robust affinity tag platform using engineered streptavidin’.

Protein 59

Protein Antibody Engineer Scientist 59

The Pharma Data

MAY 4, 2021

First-Quarter 2021 Reported Diluted EPS (1) of $0.86, Adjusted Diluted EPS (2) of $0.93. Billion and Adjusted Diluted EPS (2) to a Range of $3.55 Adjusted Income (2). Adjusted Diluted EPS (2). Adjusted Cost of Sales (2) as a Percentage of Revenues. Adjusted SI&A Expenses (2). Reported Net Income (1).

Vaccination 40

Vaccination Vaccine Production Sales 40